Hong Kong
· Delayed Price · Currency is HKD HighTide Therapeutics Company Description
HighTide Therapeutics, Inc., an biopharmaceutical company, engages in the discovery, research and development, and commercialization of therapies for the treatment of metabolic and digestive diseases in Mainland China.
Its lead drug candidate is HTD1801, which is in phase IIb clinical trial to treat metabolic dysfunction-associated steatohepatitis; in phase III clinical trial to treat type 2 diabetes mellitus; is in phase II clinical trial to treat severe hypertriglyceridemia; and in phase II clinical trial to treat primary sclerosing cholangitis, as well as in phase II clinical trial to treat primary biliary cholangitis.
The company is also developing HTD4010, a polypeptide drug, which is in phase I clinical trial for the treatment of alcoholic hepatitis; HTD1804 that is in preclinical trial to treat obesity; HTD1805, a multifunctional small molecule drug, which is in preclinical trial for the treatment of metabolic diseases; HTD4010, a Phase I clinical-stage, polypeptide drug for the treatment of complex, life-threatening diseases; HTF1057 a preclinical-stage a drug candidate for the treatment of neurodegenerative diseases; HTF1037 a preclinical-stage for the treatment of obesity and comorbidities; and HTD2802 that is in preclinical trial for treating inflammatory bowel disease.
The company was founded in 2011 and is headquartered in Shenzhen, China.
| Country | Cayman Islands |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 70 |
| CEO | Liping Liu |
Contact Details
Address: 18B-102, Zhonghaixin Innovation Industry Shenzhen, 518112 China | |
| Phone | 86 755 2662 6253 |
| Website | hightidetx.com |
Stock Details
| Ticker Symbol | 2511 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG4568L1023 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Liping Liu | Chief Executive Officer and Chairwoman |
| Meng Yu | Deputy GM and Executive Director |
| Koon Yin Sim | Chief Financial Officer |
| Liping Gao | Joint Company Secretary and Investor Relations Director |
| Dr. Leigh Anne MacConell | Chief Development Officer |
| Pik Man Chu | Joint Company Secretary |